Media headlines about Aralez Pharmaceuticals (NASDAQ:ARLZ) have trended somewhat positive on Tuesday, Accern reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aralez Pharmaceuticals earned a news impact score of 0.23 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.2950906062473 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Q3 Financials Highlight Growth – Stock News Union (blog) (stocknewsunion.com)
- Active Stocks Moving Up Today (fxpips.com)
- Edited Transcript of ARLZ earnings conference call or presentation 9-Nov-17 1:30pm GMT (finance.yahoo.com)
- Today’s Research Reports on Stocks to Watch: Aralez Pharmaceuticals and Sage Therapeutics (finance.yahoo.com)
- Aralez Pharmaceuticals Inc. (ARLZ) Issues Earnings Results (americanbankingnews.com)
Separately, Chardan Capital decreased their price objective on shares of Aralez Pharmaceuticals from $5.50 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, August 10th.
Aralez Pharmaceuticals (ARLZ) opened at $1.68 on Tuesday. The company has a debt-to-equity ratio of 4.64, a quick ratio of 0.92 and a current ratio of 1.00. Aralez Pharmaceuticals has a 52-week low of $0.95 and a 52-week high of $5.49.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.02. Aralez Pharmaceuticals had a negative net margin of 112.89% and a negative return on equity of 118.13%. The company had revenue of $24.30 million for the quarter, compared to analysts’ expectations of $22.87 million. During the same period in the prior year, the business earned ($0.32) earnings per share. Aralez Pharmaceuticals’s revenue for the quarter was up 78.7% compared to the same quarter last year. analysts expect that Aralez Pharmaceuticals will post -1.6 EPS for the current year.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.